Article
Neurosciences
Chenglu Mao, Yang Zhang, Jialiu Jiang, Ruomeng Qin, Qing Ye, Xiaolei Zhu, Jiayong Wu
Summary: This study assessed brain structure alterations related to punding in Parkinson's disease (PD) patients using MRI. The results showed that PD patients with punding had more severe cortical atrophy and worse white matter fiber tract integrity in specific areas, suggesting these findings may contribute to understanding the neural mechanisms of punding in PD.
Article
Clinical Neurology
Chi-Chuan Wang, Tsai-Ling Wu, Fang-Ju Lin, Chun-Hwei Tai, Chin-Hsien Lin, Ruey-Meei Wu
Summary: The study found that early treatment with amantadine may delay the onset of levodopa-induced dyskinesia in patients with Parkinson's disease more effectively than treatment with other symptomatic agents. Further research is needed to validate this finding and explore the mechanism by which amantadine delays LID onset.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Rajasumi Rajalingam, Alfonso Fasano
Summary: This study systematically reviewed the literature of the past decade on punding in Parkinson's disease (PD), focusing on its clinical features, underlying pathophysiological mechanisms, and treatment. The review confirmed that predictors of punding in PD are higher doses of dopamine replacement therapy, younger age, male sex, and increasing disease severity. Neuroimaging studies have shown a disconnection between midbrain, limbic and white matter tracts projecting to the frontal cortices and a breakdown of the connectivity among the crucial nodes of the reward circuit in PD patients with punding. Low-frequency repetitive transcranial magnetic stimulation on the dorsolateral prefrontal cortex has been shown to produce a transient beneficial effect.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
Qian-Ya Fan, Xiao-Dong Zhang, Ze-Di Hu, Shi-Shi Huang, Shi-Guo Zhu, Cai-Ping Chen, Xiong Zhang, Jian-Yong Wang
Summary: This case report presents a patient with Parkinson's disease who developed blepharospasm during the peak-dose dyskinesia period. The symptom was improved by taking amantadine. This expands the understanding of peak-dose dyskinesia in Parkinson's disease to include dystonic blepharospasm, which may respond to amantadine despite the dystonic appearance of movements.
FRONTIERS IN NEUROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Firoz Anwar, Salma Naqvi, Fahad A. Al-Abbasi, Nauroz Neelofar, Vikas Kumar, Ankit Sahoo, Mohammad Amjad Kamal
Summary: The global impact of the SARS-CoV-2 outbreak has put elderly Parkinson's disease (PD) patients at risk, highlighting the need for timely adjustment of treatment plans. Approved drugs for PD have established mechanisms of action, but further research is required to assess their efficacy in treating COVID-19.
CURRENT MEDICINAL CHEMISTRY
(2021)
Review
Neurosciences
Carlo Alberto Artusi, Alberto Romagnolo, Claudia Ledda, Maurizio Zibetti, Mario Giorgio Rizzone, Elisa Montanaro, Marco Bozzali, Leonardo Lopiano
Summary: Studies suggest that PD patients infected with COVID-19 have a higher case fatality rate compared to the general population, with longer disease duration potentially posing a risk. It remains uncertain whether PD patients are more susceptible to infection, but vitamin D and amantadine are proposed as potential protective factors that warrant further investigation.
JOURNAL OF PARKINSONS DISEASE
(2021)
Review
Biochemistry & Molecular Biology
Karim E. Shalaby, Omar M. A. El-Agnaf
Summary: Gene therapy has the potential to replace current treatments for Parkinson's disease and has been shown to be safe and effective in current trials.
Review
Biochemistry & Molecular Biology
Sri Jayanti, Rita Moretti, Claudio Tiribelli, Silvia Gazzin
Summary: With the increase in life expectancy, the prevalence of Parkinson's disease is expected to rise, but the diagnosis still relies on clinical symptoms. Current treatments mainly focus on alleviating symptoms without stopping or slowing down disease progression. Therefore, exploring the therapeutic potential of bilirubin in PD is crucial for the development of disease-modifying treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Clinical Neurology
Pedro Barbosa, Sean S. O'Sullivan, Eileen Joyce, Andrew J. Lees, Thomas T. Warner, Atbin Djamshidian
Summary: This study compared the clinical and neuropsychological features of Parkinson's disease patients with punding and hobbyism to PD controls. Patients with punding showed increased anxiety and frontal lobe dysfunction, while those with hobbyism exhibited similar levels of anxiety and motor fluctuations.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2022)
Article
Pharmacology & Pharmacy
Michael M. Farag, Hala Bakr El-Nassan, Hanan A. Merey, Basma Mohamed Eltanany, Maha Mohammed Galal, Walaa Wadie, Dalia M. El-Tanbouly, Mohamed A. Khattab, Laila Ahmed Rashed, Aliaa Nabil ElMeshad
Summary: Due to dysphagia and gastroparesis in Parkinson's disease (PD) patients, oral amantadine (AMT) medications have poor bioavailability and clinical outcomes. A self-given delivery system controlling AMT release was developed to improve patient compliance and therapeutic effect. The optimized formulation of AMT nano-emulsified organogel (AMT-NEO) exhibited small particle size, low polydispersity index, high zeta potential, and controlled release of AMT over 12h.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2023)
Article
Clinical Neurology
Walaa A. Kamel, Mohmed Kamel, Almunther Alhasawi, Sameh Elmasry, Fajer AlHamdan, Jasem Y. Al-Hashel
Summary: The study found that taking amantadine is associated with a reduced risk of COVID-19 infection. Old age and a history of contact with COVID cases are risk factors for COVID-19 infection.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Olivier Rascol, Lars Toenges, Tina DeVries, Mark Jaros, Adrian Quartel, David Jacobs
Summary: The study shows that IR/ER amantadine is effective in reducing LID, but the results vary in different doses and trials. However, despite some adverse events, it still has the potential to be an effective medication in the treatment of LID.
PARKINSONISM & RELATED DISORDERS
(2022)
Article
Clinical Neurology
Robert A. Hauser, Ryan R. Walsh, Rajesh Pahwa, Dustin Chernick, Andrea E. Formella
Summary: Analyzing pooled Gocovri pivotal trial data showed that the drug not only reduced troublesome dyskinesia in Parkinson's disease patients, but also significantly increased their time spent ON without any dyskinesia.
FRONTIERS IN NEUROLOGY
(2021)
Article
Crystallography
Maya Chochkova, Rusi Rusew, Reni Kalfin, Lyubka Tancheva, Maria Lazarova, Hristina Sbirkova-Dimitrova, Andrey Popatanasov, Krasimira Tasheva, Boris Shivachev, Nejc Petek, Martin Sticha
Summary: Parkinson's disease is a common neurodegenerative disorder with severe side effects associated with current treatments. In this study, a new compound, CA(2-Me)-Am, was synthesized and shown to improve memory performance and neuromuscular coordination in an experimental model of Parkinson's disease.
Article
Clinical Neurology
Filip Przytula, Jakub Kasprzak, Jaroslaw Dulski, Dariusz Koziorowski, Magdalena Kwasniak-Butowska, Witold Soltan, Anna Roszmann, Katarzyna Smilowska, Michal Schinwelski, Jaroslaw Slawek
Summary: This observational study found no significant impact of amantadine on the incidence and severity of COVID-19 infection among Parkinson's disease patients.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Neurosciences
Stefania Chiappini, Franca Ceci, Alessio Mosca, Francesco Di Carlo, Julius Burkauskas, Mauro Pettorruso, Giovanni Martinotti, Amira Guirguis, John M. M. Corkery, Norbert Scherbaum, Fabrizio Schifano, Massimo Di Giannantonio
Summary: This study aimed to explore the consumption and misuse of over-the-counter (OTC) medicines in Italy and identify the characteristics of individuals involved in this phenomenon, as well as potential risk factors. It was found that OTC misuse was associated with knowledge of the effects of OTC, while educational level appeared to be a protective factor. Therefore, increased attention and preventive strategies are needed to address OTC misuse.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Substance Abuse
Giovanni Martinotti, Giuseppe Manuel Festa, Franca Ceci, Ilenia Di Muzio, Antonino Callea, Ada Capparelli, Ludovica Bonifaci, Eleonora Chillemi, Maria Pepe, Mauro Pettorruso, Stefania Chiappini, Marco Di Nicola, Luigi Janiri
Summary: The present study aims to evaluate the psychometric properties of the CTQ-15, a revised version of CTQ with 15 items. The results show that CTQ-15 is reliable and practical for identifying the three dimensions of craving in clinical practice.
ALCOHOL AND ALCOHOLISM
(2023)
Letter
Behavioral Sciences
Giacomo d'Andrea, Mauro Pettorruso, Antea D'Andrea, Rebecca Collevecchio, Maria Chiara Santovito, Andrea Miuli, Francesco Di Carlo, Stefano L. Sensi, Giovanni Martinotti, Massimo di Giannantonio
Review
Clinical Neurology
Brent Bluett, Elissa Ash, Amtul Farheen, Alfonso Fasano, Joachim K. Krauss, Alessio Maranzano, Massimiliano Passaretti, David F. Tang-Wai, Jay Van Gerpen, Araceli Alonso-Canovas, Jinyoung Youn, Jan Malm, Davide Martino
Summary: This review evaluated the phenomenology of idiopathic normal pressure hydrocephalus (iNPH). Wide-based gait was found to be the most common gait dysfunction, while cognitive testing showed significant variations and no specific cognitive profile was identified. Urodynamic testing revealed detrusor overactivity and overactive bladder as the most common symptoms of urinary dysfunction.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Letter
Clinical Neurology
Conor Fearon, Arun E. Sundaram, Renato P. Munhoz, Alfonso Fasano, Felix Tyndel
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
(2023)
Letter
Clinical Neurology
Mauro Pettorruso, Giacomo d'Andrea, Francesco Di Carlo, Luisa De Risio, Francesca Zoratto, Andrea Miuli, Beatrice Benatti, Matteo Vismara, Enrico Pompili, Giuseppe Nicolo, Cinzia Niolu, Alberto Siracusano, Stefano S. Sensi, Bernardo Dell'Osso, Giorgio Di Lorenzo, Giovanni Martinotti
Review
Clinical Neurology
Giacomo d'Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, Gianluca Mancusi, Roger S. McIntyre, Giovanni Martinotti
Summary: Ketamine and esketamine have generated significant interest as potential therapeutic agents for Treatment-Resistant Depression (TRD). This article provides a comprehensive overview of their action and highlights their effectiveness on mixed features, anxiety, dysphoric mood, and bipolar traits. The complex pharmacodynamic mechanisms of action are discussed, and further research is needed to evaluate the efficacy of esketamine nasal spray in bipolar depression and the potential role of these substances as mood stabilizers.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Alfonso Fasano, Rocio Garcia-Ramos, Tanya Gurevich, Robert Jech, Lars Bergmann, Olga Sanchez-Solino, Juan Carlos Parra, Mihaela Simu
Summary: A multinational retrospective study found that long-term use of levodopa-carbidopa intestinal gel (LCIG) can improve motor and nonmotor symptoms in patients with Parkinson's disease, while potentially reducing the need for additional medications.
JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Stefanie Jost, Marie-Ann Kaldenbach, Angelo Antonini, Pablo Martinez-Martin, Lars Timmermann, Per Odin, Regina Katzenschlager, Rupam Borgohain, Alfonso Fasano, Fabrizio Stocchi, Nobutaka Hattori, Prashanth Lingappa Kukkle, Mayela Rodriguez-Violante, Cristian Falup-Pecurariu, Sebastian Schade, Jan Niklas Petry-Schmelzer, Vinod Metta, Daniel Weintraub, Guenther J. Deuschl, Alberto J. Espay, Eng-King Tan, Roongroj Bhidayasiri, Victor S. C. Fung, Francisco Cardoso, Claudia Trenkwalder, Peter Jenner, K. S. Ray Chaudhuri, Haidar Dafsari
Summary: This study reviewed the investigations on drug therapy for Parkinson's disease since 2010 and proposed a new drug conversion formula. These conversion formulas can help us compare drug regimens across different clinical trials. The results are important for studying the pharmacological efficacy of Parkinson's disease treatments as well as other non-pharmacological interventions.
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
Matteo Bologna, Alberto J. Espay, Alfonso Fasano, Giulia Paparella, Mark Hallett, Alfredo Berardelli
MOVEMENT DISORDERS
(2023)
Article
Psychology, Clinical
Stefania Chiappini, Alessio Mosca, Andrea Miuli, Francesco Di Carlo, Giacomo d'Andrea, Alessandra Napolitano, Monica Santangelo, Corradina Esposito, Anna Rosazza, Elena Haefele, Gilberto Di Petta, Mauro Pettorruso, Stefano L. Sensi, Giovanni Martinotti
Summary: This study aimed to investigate the role of aripiprazole once monthly as a maintenance treatment in schizophrenia patients with comorbid AUD/SUD. Clinical evaluations were conducted on a sample of 24 Italian adult patients over a period of 12 and 24 weeks, showing improvements in clinical condition, general health, and a reduction in craving for alcohol/substances. Although limited by dropouts, this study provides insights into the use of aripiprazole once monthly in patients with schizophrenia and comorbid SUD/AUD.
ADVANCES IN DUAL DIAGNOSIS
(2023)
Letter
Psychiatry
Giacomo d'Andrea, Mauro Pettorruso, Taeho Greg Rhee, Giorgio Di Lorenzo, Roger S. Mcintyre, Giovanni Martinotti
ACTA PSYCHIATRICA SCANDINAVICA
(2023)
Review
Clinical Neurology
Lindsey M. Vogt, Han Yan, Brendan Santyr, Sara Breitbart, Melanie Anderson, Juergen Germann, Karlo J. Lizarraga, Angela L. Hewitt, Alfonso Fasano, George M. Ibrahim, Carolina Gorodetsky
Summary: DBS is an effective intervention for pediatric status dystonicus, with most patients experiencing resolution of symptoms within 2 to 4 weeks post-surgery. Stimulation of the GPi region is associated with improved dystonia outcomes.
ANNALS OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Daniel G. Di Luca, Talyta C. Grippe, John Adams, Robert Chen, Alfonso Fasano, Andres Lozano, Anthony E. Lang
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Stefania Chiappini, Giacomo d'Andrea, Sergio De Filippis, Marco Di Nicola, Ileana Andriola, Roberta Bassetti, Stefano Barlati, Mauro Pettorruso, Stefano Sensi, Massimo Clerici, Bernardo Dell'Osso, Antonio Vita, Giovanni Martinotti
Summary: Esketamine has emerged as a therapy for treatment-resistant depression, showing rapid antidepressant action and good efficacy and safety. The effectiveness and safety of ESK-NS were evaluated in patients with a substance use disorder comorbid with treatment-resistant depression.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
